Browse the corpus

REFERENCES Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 1992; 19:303. Slatopolsky E. The interaction of parathyroid hormone and aluminum in renal osteodystrophy. Kidney Int 1987; 31:842. Cannata-Andía JB, Fernández-Martín JL. The clinical impact of aluminium overload in renal failure. Nephrol Dial Transplant 2002; 17 Suppl 2:9. Salusky IB, Foley J, Nelson P, Goodman WG. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 1991; 324:527. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1. Jaffe JA, Liftman C, Glickman JD. Frequency of elevated serum aluminum levels in adult dialysis patients. Am J Kidney Dis 2005; 46:316. Centers for Disease Control and Prevention (CDC). Elevated serum aluminum levels in hemodialysis patients associated with use of electric pumps--Wyoming, 2007. MMWR Morb Mortal Wkly Rep 2008; 57:689. Bohrer D, Bertagnolli DC, de Oliveira SM, et al. Drugs as a hidden source of aluminium for chronic renal patients. Nephrol Dial Transplant 2007; 22:605. Netter P, Kessler M, Burnel D, et al. Aluminum in the joint tissues of chronic renal failure patients treated with regular hemodialysis and aluminum compounds. J Rheumatol 1984; 11:66. Andress DL, Kopp JB, Maloney NA, et al. Early deposition of aluminum in bone in diabetic patients on hemodialysis. N Engl J Med 1987; 316:292. Pei Y, Hercz G, Greenwood C, et al. Renal osteodystrophy in diabetic patients. Kidney Int 1993; 44:159. Vincenti F, Arnaud SB, Recker R, et al. Parathyroid and bone response of the diabetic patient to uremia. Kidney Int 1984; 25:677. Santiago JV, McAlister WH, Ratzan SK, et al. Decreased cortical thickness & osteopenia in children with diabetes mellitus. J Clin Endocrinol Metab 1977; 45:845. Vincenti F, Hattner R, Amend WJ Jr, et al. Decreased secondary hyperparathyroidism in diabetic patients receiving hemodialysis. JAMA 1981; 245:930. Touam M, Martinez F, Lacour B, et al. Aluminium-induced, reversible microcytic anemia in chronic renal failure: clinical and experimental studies. Clin Nephrol 1983; 19:295. Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 1976; 294:184.

Vincenti F, Hattner R, Amend WJ Jr, et al. Decreased secondary hyperparathyroidism in diabetic patients receiving hemodialysis. JAMA 1981; 245:930. Touam M, Martinez F, Lacour B, et al. Aluminium-induced, reversible microcytic anemia in chronic renal failure: clinical and experimental studies. Clin Nephrol 1983; 19:295. Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 1976; 294:184. Harrington CR, Wischik CM, McArthur FK, et al. Alzheimer's-disease-like changes in tau protein processing: association with aluminium accumulation in brains of renal dialysis patients. Lancet 1994; 343:993. Nolan CR, Califano JR, Butzin CA. Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int 1990; 38:937. Walker JA, Sherman RA, Cody RP. The effect of oral bases on enteral aluminum absorption. Arch Intern Med 1990; 150:2037. Chazan JA, Abuelo JG, Blonsky SL. Plasma aluminum levels (unstimulated and stimulated): clinical and biochemical findings in 185 patients undergoing chronic hemodialysis for 4 to 95 months. Am J Kidney Dis 1989; 13:284. McCarthy JT, Milliner DS, Johnson WJ. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity. Q J Med 1990; 74:257. Kausz AT, Antonsen JE, Hercz G, et al. Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. Am J Kidney Dis 1999; 34:688. Milliner DS, Nebeker HG, Ott SM, et al. Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy. Ann Intern Med 1984; 101:775. Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 1991; 18:660. D'Haese PC, Couttenye MM, Goodman WG, et al. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload. Nephrol Dial Transplant 1995; 10:1874. Malluche HH, Smith AJ, Abreo K, Faugere MC. The use of deferoxamine in the management of aluminium accumulation in bone in patients with renal failure. N Engl J Med 1984; 311:140. Felsenfeld AJ, Rodriguez M, Coleman M, et al. Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease. Kidney Int 1989; 35:1371.

Malluche HH, Smith AJ, Abreo K, Faugere MC. The use of deferoxamine in the management of aluminium accumulation in bone in patients with renal failure. N Engl J Med 1984; 311:140. Felsenfeld AJ, Rodriguez M, Coleman M, et al. Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease. Kidney Int 1989; 35:1371. Molitoris BA, Alfrey AC, Alfrey PS, Miller NL. Rapid removal of DFO-chelated aluminum during hemodialysis using polysulfone dialyzers. Kidney Int 1988; 34:98. Barata JD, D'Haese PC, Pires C, et al. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules. Nephrol Dial Transplant 1996; 11:125. Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986; 314:869. Sherrard DJ, Walker JV, Boykin JL. Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease. Am J Kidney Dis 1988; 12:126. Knudsen PJ, Leon J, Ng AK, et al. Hemodialysis-related induction of beta-2-microglobulin and interleukin-1 synthesis and release by mononuclear phagocytes. Nephron 1989; 53:188. Ellenberg R, King AL, Sica DA, et al. Cerebrospinal fluid aluminum levels following deferoxamine. Am J Kidney Dis 1990; 16:157. Topic 1839 Version 5.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0504-115.25.216.6-3A7D25EF8E-S244013.14]